A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
There is an urgent need for effective treatments targeting comorbidities of type 2 diabetes (T2DM) and obesity. Developing dual agonists of glucagon-like peptide 1 receptor (GLP-1R) and neuropeptide Y receptor type 2 (NPY2R) with combined PYYand GLP-…
: There has been a prominent rise in the use of GLP-1 RAs recently, particularly semaglutide, for the treatment of T2DM with or without obesity. Subcutaneous injections of semaglutide have demonstrated beneficial effects on cardiovascular risk factor…
OBJECTIVE: Investigate the impact and mechanism of semaglutide (Sema) combined with high-intensity interval training (HIIT) on hepatic glucose/lipid metabolism in db/db mice using untargeted metabolomics. METHODS: Db/db mice were divided into model c…
CONTEXT: Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed. OBJECTIV…
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a chronic disease that substantially increases morbidity and mortality through its cardiovascular and renal complications. Beyond mere glycemic control, current guidelines from the European Society of…
INTRODUCTION: The expanding range of therapeutic options for type 2 diabetes (T2D) calls for a reassessment of clinical scenarios in which existing glucose-lowering therapies might be substituted with the oral glucagon-like peptide 1 receptor agonist…
Semaglutide and liraglutide are long-acting glucagon-like peptide-1 receptor agonists used to treat type-2 diabetes and obesity. Recent advances in peptide synthesis and analytical technologies have enabled the development of synthetic generic peptid…
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and ti…
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advancednon-small cell lung cancer (NSCLC) ever since its approved indication on November 17,…
Background Incretin-based therapies have emerged as effective strategies for obesity and type 2 diabetes mellitus (T2DM) management. Semaglutide and tirzepatide are among the most promising agents. Real-world data in Bangladesh on their efficacy, lif…
This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in the treatment of obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy in weight reduction, with sup…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are long-acting drugs that have gathered a lot of attention worldwide for their utility in the treatment landscape of type 2 diabetes mellitus and obesity. Their widespread global use has been acco…
OBJECTIVE: This proof-of-concept study evaluated the impact of adding semaglutide as an adjuvant therapy to sleeve gastrectomy (SG) on weight loss and metabolic outcomes in obese mice. METHODS: C57Bl6/J male received for 12 weeks high-fat diet and 20…
IMPORTANCE: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications. OBJECTIVE: To report ophthalmic…
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated substantial efficacy in managing type 2 diabetes mellitus (T2DM). It provides glycemic control, promotes weight loss, and offers cardiovascular protection. Evidence a…
BACKGROUND: Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment u…
BACKGROUND: There is a pressing requirement to formulate innovative approaches for addressing inadequate weight loss or recurrence in individuals following metabolic bariatric surgery (MBS). Glucagon-like peptide- 1 (GLP- 1) analogues such as liraglu…
INTRODUCTION: Semaglutide 2.4 mg (Wegovy) is the first second-generation anti-obesity medication approved by the FDA for long-term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first-generation anti-obesity medications…